Extensive cutaneous necrosis in infective endocarditis: do not forget rare causes
A 54-year-old man was admitted through the emergency department of a local hospital with fever and large cutaneous necrotic lesions covering 20% of the body sur
Related Articles
Research Project Coordinator, Entry in Portland, Oregon | Careers at Portland, OR (Marquam Hill)
The Knight Cardiovascular Institute Research Project Coordinator acts as a key staff member to our Cardiology Clinical Trials program. They are assigned a focused area…
National and Regional Medicare Spending on Tafamidis, 2019-2021
This cross-sectional study describes national and regional Medicare spending and out-of-pocket costs for tafamidis from its approval in 2019 to 2021.
Contemporary Management of Hypertrophic Cardiomyopathy: Key Challenges, Recent Advances, and Future Directions
EP Lab Digest speaks with Ahmad Masri, MD, MS, about contemporary management of hypertrophic cardiomyopathy, including recent advances, pharmacologic treatment options, new guidelines, and future…
Aficamten and Cardiopulmonary Exercise Test Performance
This substudy of the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive Hypertrophic…
ClinicalTrials.gov
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy:
AbstractBackgroundAficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with s…
Instructor/Advanced Practice Provider in Portland, Oregon | Careers at Portland, OR (Waterfront)
This advanced practice provider position provides care to patients primarily in the outpatient setting but may include inpatient care and consultation as well. The clinic…
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion (+14%…
Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM
Aims The aim of this study was to report safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the…